The 45 references in paper Н. Воробьева М., Е. Панченко П., Н. Воробьева М., Е. Панченко П. (2013) “НОВЫЕ ПЕРОРАЛЬНЫЕ АНТИКОАГУЛЯНТЫ И АЦЕТИЛСАЛИЦИЛОВАЯ КИСЛОТА В ЛЕЧЕНИИ ВЕНОЗНЫХ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ” / spz:neicon:aterotromboz:y:2013:i:1:p:53-65

1
Goldhaber S.Z., Bounameaux H. Pulmonary embolism and deep vein thrombosis // Lancet. 2012. No379. Р. 1835–1846.
(check this in PDF content)
2
Spencer F.A., Emery C., Lessard D. et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism // J. Gen Intern. Med. 2006. No21. Р. 722–727.
(check this in PDF content)
3
Christiansen S.C., Cannegieter S.C., Koster T. et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events // JAMA. 2005. No293. Р. 2352–2361.
(check this in PDF content)
4
Kearon C., Akl E.A., Comerota A.J. et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis. 9th ed.: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines. Chest 2012. No141. Suppl. Р. e 419S– e 494 S.
(check this in PDF content)
5
Eriksson B.I., Dahl O.E., RosencherN. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial // J. Thromb. Haemost. 2007. No5. Р. 2178–2185.
(check this in PDF content)
6
Eriksson B.I., Dahl O.E., Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial // Lancet. 2007. No370. Р. 949–956.
(check this in PDF content)
7
Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009. No 361. P. 1139–1151.
(check this in PDF content)
8
Schulman S., Kearon C., Kakkar A.K. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism // N. Engl. J. Med. 2009. No361. Р. 2342–2352.
(check this in PDF content)
9
Turpie A.G., Lassen M.R., Eriksson B.I. et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies // Thromb. Haemost. 2011. No105. Р. 444–453.
(check this in PDF content)
10
Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation // N. Engl. J. Med. 2011. No365. Р. 883–891.
(check this in PDF content)
11
Mega J.L., Braunwald E., Wiviott S.D. et al. Rivaroxaban in patients with a recent acute coronary syndrome // N. Engl. J. Med. 2012. No66. Р. 9–19.
(check this in PDF content)
12
Buller H.R., Lensing A.W.A., Prins M.H. et al. A doseranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study // Blood. 2008. No112. Р. 2242–2247.
(check this in PDF content)
13
Agnelli G., Gallus A., Goldhaber S.Z. et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study // Circulation. 2007. No116. Р. 180–187.
(check this in PDF content)
14
Barritt D.W., Jordan S.C. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial // Lancet. 1960. No1. Р. 1309–1312.
(check this in PDF content)
15
The van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease // N. Engl. J. Med. 2007. No357. Р. 1094–1104.
(check this in PDF content)
16
Brandjes D.P.M., Heijboer H., Buller H.R. et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis // N. Engl. J. Med. 1992. No327. Р. 1485–1489.
(check this in PDF content)
17
Fiessinger J.N., Huisman M.V., Davidson B.L. et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial // JAMA. 2005. No293. Р. 681–689.
(check this in PDF content)
18
Mueck W., Lensing A.W., Agnelli G. et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention // Clin. Pharmacokinet. 2011. No50. Р. 675–686.
(check this in PDF content)
19
The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism // N. Engl. J. Med. 2010. No363. Р 2499–2510.
(check this in PDF content)
20
The EINSTEIN-PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism // N. Engl. J. Med. 2012. No366. Р. 1287–1297.
(check this in PDF content)
21
Schafer A.I. Venous thrombosis as a chronic disease // N. Engl. J. Med. 1999. No340. Р. 955–956.
(check this in PDF content)
22
Prandoni P., Lensing A.W., Cogo A. et al. The longterm clinical course of acute deep venous thrombosis //Ann. Intern. Med. 1996. No125. Р. 1–7.
(check this in PDF content)
23
Schulman S., Rhedin A-S., Lindmarker P. et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism // N. Engl. J. Med. 1995. No332. Р. 1661–1665.
(check this in PDF content)
24
Agnelli G., Prandoni P., Santamaria M.G. et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis // N. Engl. J. Med. 2001. No345. Р. 165–169.
(check this in PDF content)
25
Agnelli G., Prandoni P., Becattini C. et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism // Ann. Intern. Med. 2003. No139. Р. 19–25.
(check this in PDF content)
26
Kearon C., Gent M., Hirsh J. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism // N. Engl. J. Med. 1999. No340. Р. 901–907.
(check this in PDF content)
27
Granger C.B., Alexander J.H., McMurray J.J. et al. Apixaban versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. 2011. No365. Р. 981–992.
(check this in PDF content)
28
Connolly S.J., Eikelboom J., Joyner C. et al. Apixaban in patients with atrial fibrillation // N. Engl. J. Med. 2011. No364. Р. 806–817.
(check this in PDF content)
29
Raskob G.E., Gallus A.S., Pineo G.F. et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials // J. Bone. Joint Surg. Br. 2012. No94. Р. 257–264.
(check this in PDF content)
30
Agnelli G., Buller H.R., Cohen A. et al. for the AMPLIFY-EXT Investigators. Apixaban for Extended Treatment of Venous Thromboembolism // N. Engl. J. Med. 2013. No368. Р. 699–708.
(check this in PDF content)
31
Steele P. Trial of dipyridamole-aspirin in recurring venous thrombosis // Lancet. 1980. No2. Р. 1328–1329.
(check this in PDF content)
32
Becattini C., Agnelli G., Schenone A. et al. Aspirin for Preventing the Recurrence of Venous Thromboembolism // N. Engl. J. Med. 2012. No366. Р. 1959–1967.
(check this in PDF content)
33
Brighton T.A., Eikelboom J.W., Mann K. et al. LowDose Aspirin for Prevention Recurrent Venous Thromboembolism // N. Engl. J. Med. 2012. No367. Р. 1979–1987.
(check this in PDF content)
34
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients // BMJ. 1994. No308. Р. 235–246.
(check this in PDF content)
35
Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial // Lancet. 2000. No355. Р. 1295–1302.
(check this in PDF content)
36
Grady D., Wenger N.K., Herrington D. et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study // Ann. Intern. Med. 2000. No132. Р. 689–696.
(check this in PDF content)
37
Becattini C., Agnelli G., Prandoni P. et al. A prospective study on cardiovascular events after acute pulmonary embolism // Eur. Heart. J. 2005. No26. Р. 77–83.
(check this in PDF content)
38
Patrono C., Baigent C., Hirsh J., Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008. No133. Suppl. Р. 199 S–233 S.
(check this in PDF content)
39
Linkins L.A., Choi P.T., Douketis J.D. Clinical impact of bleeding in patients taking oral anticoagulant therapy for with venous thromboembolism: a meta-analysis // Ann. Intern. Med. 2003. No139. Р. 893–900.
(check this in PDF content)
40
Ridker P.M., Goldhaber S.Z., Danielson E. et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism // N. Engl. J. Med. 2003. No348. Р. 1425–1434.
(check this in PDF content)
41
Kearon C., Ginsberg J.S., Kovacs M.J. et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism // N. Engl. J. Med. 2003. No349. Р. 631–639.
(check this in PDF content)
42
Schulman S., Eriksson H., Goldhaber S.Z. et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism // J. Thromb. Haemost. 2011. No9. Suppl. 2. Р. 731–732.
(check this in PDF content)
43
Schulman S., Baanstra D., Eriksson H. et al. Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism // J. Thromb. Haemost. 2011. No9. Suppl. 2. Р. 22–22.
(check this in PDF content)
44
Воробьева Н.М., Панченко Е.П., Ермолина О.В. и др. Продление терапии эноксапарином до одного месяца способствует реканализации окклюзивно тромбированных глубоких вен // Терапевтический архив. 2011. Т. 83. No8. С. 33–37.
(check this in PDF content)
45
Воробьева Н.М., Панченко Е.П., Добровольский А.Б. [и др.] Независимые предикторы рецидива тромбоза глубоких вен (результаты проспективного 18-месячного наблюдения) // Кардиология. 2010. Т. 50. No12. С. 52–58.
(check this in PDF content)